Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148

Trial Profile

Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
    • 01 May 2018 Results published in the European Urology 2018
    • 06 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top